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Single-dose liposomal amphotericin B: an eﬀ ective treatment 
for visceral leishmaniasis
Visceral leishmaniasis (also known as kala-azar) is a 
vector-borne disease transmitted through the bite of 
female phlebotomine sandﬂ ies. It is carried by people in 
the Indian subcontinent (India, Nepal, and Bangladesh) 
and human beings are the only disease reservoir. 
Clinical features are characterised by fever, weight loss, 
hepatosplenomegaly, and pancytopenia; the disease is 
typically fatal if untreated. Early diagnosis and eﬀ ective 
treatment are thus key to the management of patients 
with visceral leishmaniasis.
Since the 1920s, the mainstay of treatment 
for visceral leishmaniasis has been antimonials. 
Upendranath Brahmachari ﬁ rst treated patients 
with visceral leishmaniasis in Bengal and Assam with 
the antimonial urea stibamine. After the 1940s, 
pentavalent antimony compounds such as sodium 
antimony gluconate (sodium stibogluconate) began 
to be used to treat patients. However, because of their 
ineﬀ ectiveness in endemic districts in north Bihar and 
adjoining districts of Nepal from the 1980s, improved 
treatment options were needed.1 When responsiveness 
to sodium antimony gluconate became less than 50%, 
it was replaced by amphotericin B deoxycholate, which 
had cure rates of more than 95%. However, infusion of 
this drug is associated with adverse eﬀ ects such as rigor, 
fever, and occasional nephrotoxicity.
In the past two decades, three important drugs for 
the treatment of visceral leishmaniasis have been 
registered in India, Nepal, and Bangladesh after positive 
clinical trials: liposomal amphotericin B, miltefosine, 
and paromomycin. Liposomal amphotericin B has 
shown much the same activity as amphotericin B 
deoxycholate, but with lesser infusion-related adverse 
eﬀ ects owing to liposomal encapsulation of the active 
ingredient. Relatively uncommon side-eﬀ ects related 
to infusion of liposomal amphotericin B include chest 
tightness, low blood pressure, and back or bone pain; 
these side-eﬀ ects are reversible soon after the infusion 
is stopped. To date, however, multidose liposomal 
amphotericin B has mainly been used as rescue therapy 
because of its high cost. Nevertheless, this regimen 
has key advantages compared with other drugs such 
as miltefosine (which requires 28 days of oral therapy) 
and paromomycin (which requires 21 intramuscular 
injections).
In Dinesh Mondal and colleagues’ new study2 in 
The Lancet Global Health, the ﬁ nal cure rate at 6 months 
after treatment with 10 mg/kg liposomal amphotericin B 
at the primary health-care level in Bangladesh was 97%, 
with few side-eﬀ ects that were easily manageable at the 
primary-health care level. No patients needed referral 
to the tertiary hospital for management of adverse 
events. However, one patient had hypersensitivity to 
liposomal amhpotericin and another had interruption 
of treatment during intravenous infusion because of 
development of bradycardia. Six treated patients had a 
decrease in haemoglobin by 2 g/L. A notable proportion 
of patients with visceral leishmaniasis (27%) were 
hypotonic, meaning that medical staﬀ  should therefore 
be trained for its management before start of treatment 
at peripheral level. These ﬁ ndings add to those from 
another study in Bihar, India, in which a single dose 
(10 mg/kg) of liposomal amphotericin B was eﬀ ective 
in 96% of participants at 6 months.3 Thus, liposomal 
amphotericin B can be said to have high cure rates, low 
relapse rates, few side-eﬀ ects related to infusion, and 
good rates of treatment compliance.
The ideal drug to reduce disease burden and prevent 
relapse and post-kala-azar dermal leishmaniasis will 
need to be eﬀ ective, cheap, usable at the peripheral 
level, and have a strong safety proﬁ le. Mondal 
and colleagues2 show for the ﬁ rst time that single-
dose liposomal amphotericin B could meet all such 
expectations. A particular advantage is that it can be 
used in children and women of childbearing age without 
any contraceptive precautions. Conversely, miltefosine, 
an oral drug brought into the visceral leishmaniasis 
elimination programme as the ﬁ rst-line therapy in many 
of the endemic districts of India, is contraindicated in 
pregnancy and breastfeeding and, because of its long 
half-life, a high potential for development of resistance 
exists. Notably, a decrease in eﬃ  cacy of miltefosine from 
97% in the phase 3 trial3 to 82% in the phase 4 trial4 at 
6 months was shown in India. Additionally, single-dose 
liposomal amphotericin B has advantages such as near 
100% compliance (one-oﬀ  administration) compared 
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with other regimens such as sodium antimony 
gluconate, miltefosine, or amphotericin B deoxycholate. 
The major concern is that monotherapy can foster 
emergence of drug resistance. Other important factors 
are the cost of treatment and the fact that a proper 
cold chain must be maintained and standard operating 
procedure followed. However, the cost of liposomal 
amphotericin B has recently been dropped, and single-
dose treatment could reduce costs associated with non-
medical transportation and hospital stays. Mondal and 
colleagues’ study shows the feasibility of the drug’s use 
under “real-life” conditions.
The Drugs for Neglected Diseases Initiative and 
WHO’s Special Programme for Research and Training 
in Tropical Diseases are presently undertaking 
studies to assess the feasibility, safety, and eﬃ  cacy of 
treatment with single-dose liposomal amphotericin B 
10 mg/kg for the management of visceral leishmaniasis 
in endemic regions at district hospitals and primary 
health-care services in Bihar, India. The Drugs for 
Neglected Diseases Initiative is also assessing the 
safety and eﬃ  cacy of diﬀ erent combination regimens, 
including miltefosine and paromomycin for 10 days, 
and single-dose liposomal amphotericin B 5 mg/kg 
and miltefosine for 7 days at a district hospital and the 
primary health-care level in Bihar, India.
WHO’s expert committee on the control of 
leishmaniasis (WHO Technical Report Series no 949)5 in 
its 2010 meeting recommended the use of liposomal 
amphotericin B, 10 mg/kg, as single infusion as a ﬁ rst 
choice for the treatment of anthroponotic visceral 
leishmaniasis in the Indian subcontinent. In our opinion, 
single-dose treatment with liposomal amphotericin B will 
indeed be the most eﬀ ective and best drug to treat poor 
patients with visceral leishmaniasis at primary health-care 
level in the visceral leishmaniasis elimination programme 
undertaken by India, Bangladesh, and Nepal, and will thus 
help to reduce the burden of the disease in this region.
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